SCHEMBL30765488

SCHEMBL30765488

O=C(Cn1c(-c2ccccc2)ncc(NC(=O)c2cccc(-c3nccs3)c2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 5/20 0.46
HDAC2 Q92769 1/20 0.40
CASP1 P29466 1/20 0.39
CMA1 P23946 4/20 0.38
KAT6A Q92794 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
NTRK3 Q16288 1/20 0.38
ELANE P08246 5/20 0.38
F3 P13726 1/20 0.37
CTRC Q99895 2/20 0.36
HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765637 0.94 HDAC1 (0.41) NTRK1HDAC2CASP1CMA1NTRK3
SCHEMBL31558568 0.87 NTRK1 (0.45) NTRK1HDAC2CASP1CMA1NTRK3
SCHEMBL30765478 0.86 CASP1 (0.41) NTRK1CASP1CMA1MAPK8MAPK9
SCHEMBL30765954 0.84 HDAC1 (0.40) NTRK1HDAC2CASP1CMA1NTRK3
SCHEMBL30765974 0.83 CASP1 (0.44) NTRK1HDAC2CASP1CMA1NTRK3
SCHEMBL30766106 0.82 NTRK1 (0.54) NTRK1HDAC2CASP1CMA1KAT6A
SCHEMBL31558593 0.81 CMA1 (0.39) NTRK1CMA1NTRK3F3CTRC
SCHEMBL30765697 0.81 F2 (0.43) NTRK1CASP1CMA1NTRK3ELANE
SCHEMBL30766005 0.81 CASP1 (0.41) NTRK1CASP1CMA1NTRK3ELANE
SCHEMBL30765851 0.81 NTRK1 (0.40) NTRK1HDAC2CASP1CMA1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed